Glenmark Pharma Q4FY22 Results: Consolidated profit dips 26% at Rs 173 cr, company announces dividend
Consolidated revenues of the drug firm, however, rose to Rs 3,019 crore in the quarter under review as compared to Rs 2,860 crore in the year-ago period.
For the year ended March 31, 2022, the Mumbai-based drug firm reported a PAT of Rs 994 crore: Pixabay